<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01835262</url>
  </required_header>
  <id_info>
    <org_study_id>12/09/VA01</org_study_id>
    <secondary_id>12-09-VA01</secondary_id>
    <nct_id>NCT01835262</nct_id>
  </id_info>
  <brief_title>Low Dose Ketamine Versus Morphine for Moderate to Severe Pain in the Emergency Department</brief_title>
  <official_title>Low Dose Ketamine Versus Morphine for Moderate to Severe Pain in the Emergency Department: A Prospective, Randomized, Double-Blind Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Antonios Likourezos</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maimonides Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of the study are to evaluate the efficacy of subdissociative dose
      intravenous ketamine compared with intravenous morphine in relieving acute pain in the ED.
      Secondary objectives will include the rate of adverse effects and need for rescue analgesia.
      The hypothesis is that intravenous administration of subdissociative dose ketamine at 0.3
      mg/kg is superior to intravenous morphine at 0.1mg/kg in treating moderate and severe acute
      pain in patients presenting to the ED.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale: Opioids are traditionally accepted as a cornerstone of acute pain management in
      the Emergency Department (ED). Morphine is one of the most commonly used parenteral opioid
      analgesics whose initial dose of 0.1 mg/kg has been extensively researched and recommended
      for control of severe acute pain in the ED. However, intravenous administration of opioids is
      associated with thefollowing side effects: hypotension, respiratory depression, dizziness,
      pruritis and nausea. In addition, in patients with pre-existing renal and/or hepatic
      insufficiency, these effects may be pronounced and require interventions. Thus, the
      administration of an equipotent analgesic that does not cause hypotension and respiratory
      depression would enhance patient safety in the ED.

      Ketamine is a noncompetitive N-methyl D-aspartate (NMDA) receptor antagonist that blocks the
      release of excitatory neurotransmitter glutamate and provides anesthesia, amnesia and
      analgesia by virtue of decreasing central sensitization and &quot;wind-up&quot; phenomenon. Due to its
      high lipid solubility, ketamine rapidly crosses the blood-brain barrier, provides rapid onset
      of action (peak concentration at is reached 1 minute after IVP) and rapid recovery to
      baseline (duration of action 5-15 minutes after IVP) (1). When given at subdissociative doses
      of 0.1-0.5 mg/kg, either as an adjunct to opioid analgesic or as a solo agent, ketamine
      provides good analgesia while preserving airway patency, ventilation, and cardiovascular
      stability (2). In addition, a small dose of ketamine may increase the analgesic potency of
      opioids thus decreasing their dosing requirements (3). Based on the aforementioned facts,
      ketamine offers an attractive option for providing safe and convenient pain control for
      patients in the ED.

      A double-blind trial of 40 adult patients with acute musculoskeletal trauma compared low-dose
      ketamine administered by subcutaneous infusion (0.1 mg/kg/h) with intermittent intravenous
      morphine (0.1 mg/kg IV every 4 hours ) and demonstrated better pain relief, less sedation and
      less nausea and vomiting with ketamine infusion than with intermittent morphine. In addition,
      none of the patients in the ketamine group required supplementary analgesia (4). A
      prospective, randomized trial compared two analgesic regimens, morphine with ketamine (K
      group) or morphine with placebo (P group) for severe acute pain in 73 trauma patients with a
      visual analog scale (VAS) score of at least 60/100. Morphine was administered at 0.1mg/kg;
      patients in the K group received 0.2 mg/kg of intravenous ketamine over 10 minutes while
      patients in the P group received isotonic sodium chloride solution. The results showed
      comparable change in VAS score at 30 minutes (34 mm (K) vs. 39 mm (P)) but reduced morphine
      consumption in the ketamine group (0.14 mg/kg (K) vs 0.2 mg/kg (P)) (5).

      A chart review analysis of 35 ED patients receiving low dose ketamine at doses 0.1mg-0.6mg/kg
      in addition to intravenous morphine demonstrated a decrease in pain intensity for 54% of the
      patients by a documented 3 point pain decrease on a 10-point scale. The ketamine doses ranged
      from 5 mg to 35 mg with median dose of 10 mg and mean dose of 15.7mg. In addition, only one
      patient had a brief dysphoric reaction that did not require intervention (6).

      Hypothesis: Intravenous administration of subdissociative dose ketamine at 0.3 mg/kg is
      superior to intravenous morphine at 0.1 mg/kg in treating moderate and severe acute pain in
      patients presenting to the ED.

      Methods: Prospective, randomized, double-blind trial evaluating and comparing analgesic
      effect of intravenous Ketamine administered in sub-dissociative doses: 0.3 mg/kg given over
      10 minutes with intravenous Morphine given at 0.1mg/kg as a single IVP.

      Description: Once patient is triaged, an initial pain score will be assessed and patient's
      stated weight will be recorded in the chart. Patients will then have an initial evaluation by
      an attending ED physician and once found to be eligible for the study (deemed by treating
      physician to warrant administration of intravenous analgesia) patient will be randomized to
      receive either morphine at 0.1 mg /kg given as IVP or ketamine at 0.3 mg/given as IVP.
      Patients' vital signs will be recorded at triage, at the beginning of the study and at 15,
      30, 60, 90, 120 minutes post-administration. Patients will be placed on a monitor and
      continuous pulse oximetry (oxygen saturation), blood pressure, heart rate and respiratory
      rate will be recorded. We will compare efficacy as a difference between 2 groups in pain
      relief from the baseline (at triage) to 30 minutes post-analgesic administration. The primary
      outcome is the difference between 2 groups in pain relief at 30 minutes. The secondary
      outcome is side effects. We will compare the safety profile of each analgesic with respect to
      incidence of hypotension, respiratory depression, nausea and vomiting, pruritis, need for an
      opioid reversal agent (naloxone), tachycardia, laryngospasm, hypersalivation, dizziness,
      agitation and need for benzodiazepines (midazolam) administration for symptomatic evidence of
      emergence reaction. All the data will be entered and analyzed via SPSS. Data analyses will
      include frequency distributions, and ANOVA to assess a difference in pain scores between the
      groups at various time points. All patients will be analyzed with an intent to treat
      analysis. However, a subgroup analysis will be done for any emergence reaction or event which
      occurs often.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Numeric Rating Scale of Pain</measure>
    <time_frame>30 minutes</time_frame>
    <description>We will compare efficacy as a difference between 2 groups in pain score at 30 minutes post-analgesic administration. The primary outcome is the difference between 2 groups in pain score at 30 minutes.
Pain will be measured via Numeric rating scale from 0 to 10 with 0 being no pain, 5 being moderate pain, and 10 being severe pain</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Morphine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Morphine Group -- Receiving morphine at 0.1 mg /kg given as IVP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketamine Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ketamine Group - - Receiving ketamine at 0.3 mg/given as IVP</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <description>Morphine: 0.1 mg /kg given as IVP</description>
    <arm_group_label>Morphine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Ketamine:0.3 mg/given as IVP</description>
    <arm_group_label>Ketamine Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ED patients18-55 years old presenting with moderate to severe (Numeric Pain Rating
             Score &gt;5) acute (less than 7 days)

          2. abdominal, flank, back or musculoskeletal pain warranting (in the treating physician's
             judgment) administration of intravenous opioid pain medication.

          3. Patients must be awake, alert and oriented to time, place and person,

          4. patient must be able to demonstrate understanding of the informed consent.

          5. Patient must be able to verbalize how much pain they are having on the 10 point
             Numeric Rating Pain Scale,

          6. Patient mus be able to verbalize the nature of the side effects he may be experiencing
             from the intravenous analgesia.

        Exclusion Criteria:

          1. Pregnancy or breast feeding

          2. SBP&lt;90

          3. Weight greater than 115kg or less than 45kg,

          4. altered mental status,

          5. allergy to ketamine or morphine,

          6. history of acute head or ocular trauma

          7. presence of intracranial mass or vascular lesion, presence of psychiatric history

          8. diagnosis or treatment (as assessed by electronic chart review).

          9. history of seizure or intracranial hypertension

         10. history of chronic pain, pain syndrome or fibromyalgia

         11. presence of cardiovascular disease except controlled hypertension

         12. history of acute head or ocular trauma, drug or alcohol abuse in the preceding 6
             months

         13. drugs or alcohol abuse in the preceding 6 months

         14. SBP&gt;180

         15. HR&lt;50

         16. HR&gt;150

         17. RR&lt;10

         18. RR&gt;30

         19. administration of opiate pain medication in the past 4 hours prior to assessment (i.e.
             home, EMS, triage, office, etc.)

         20. presence of renal or hepatic insufficiency (as assessed by electronic chart review),
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sergey Motov, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maimonides Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maimonides Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Winterfield RW, Fadly AM, Hoerr FJ. Vaccination and revaccination with a Holland (H) strain of infectious bronchitis virus. Avian Dis. 1976 Apr-Jun;20(2):369-74.</citation>
    <PMID>180959</PMID>
  </reference>
  <reference>
    <citation>Javery KB, Ussery TW, Steger HG, Colclough GW. Comparison of morphine and morphine with ketamine for postoperative analgesia. Can J Anaesth. 1996 Mar;43(3):212-5.</citation>
    <PMID>8829857</PMID>
  </reference>
  <reference>
    <citation>Gurnani A, Sharma PK, Rautela RS, Bhattacharya A. Analgesia for acute musculoskeletal trauma: low-dose subcutaneous infusion of ketamine. Anaesth Intensive Care. 1996 Feb;24(1):32-6.</citation>
    <PMID>8669651</PMID>
  </reference>
  <reference>
    <citation>Galinski M, Dolveck F, Combes X, Limoges V, Sma√Øl N, Pommier V, Templier F, Catineau J, Lapostolle F, Adnet F. Management of severe acute pain in emergency settings: ketamine reduces morphine consumption. Am J Emerg Med. 2007 May;25(4):385-90.</citation>
    <PMID>17499654</PMID>
  </reference>
  <reference>
    <citation>Lester L, Braude DA, Niles C, Crandall CS. Low-dose ketamine for analgesia in the ED: a retrospective case series. Am J Emerg Med. 2010 Sep;28(7):820-7. doi: 10.1016/j.ajem.2009.07.023. Epub 2010 Apr 2.</citation>
    <PMID>20837262</PMID>
  </reference>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2013</study_first_submitted>
  <study_first_submitted_qc>April 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2013</study_first_posted>
  <results_first_submitted>July 29, 2015</results_first_submitted>
  <results_first_submitted_qc>July 29, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 27, 2015</results_first_posted>
  <last_update_submitted>January 29, 2016</last_update_submitted>
  <last_update_submitted_qc>January 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Maimonides Medical Center</investigator_affiliation>
    <investigator_full_name>Antonios Likourezos</investigator_full_name>
    <investigator_title>Research Manager</investigator_title>
  </responsible_party>
  <keyword>pain</keyword>
  <keyword>Ketamine</keyword>
  <keyword>Emergency Medicine</keyword>
  <keyword>morphine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emergencies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Morphine</title>
          <description>Morphine Group -- Receiving morphine at 0.1 mg /kg given as IVP
Morphine: Morphine: 0.1 mg /kg given as IVP</description>
        </group>
        <group group_id="P2">
          <title>Ketamine Group</title>
          <description>Ketamine Group - - Receiving ketamine at 0.3 mg/given as IVP
Ketamine: Ketamine:0.3 mg/given as IVP</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Morphine</title>
          <description>Morphine Group -- Receiving morphine at 0.1 mg /kg given as IVP
Morphine: Morphine: 0.1 mg /kg given as IVP</description>
        </group>
        <group group_id="B2">
          <title>Ketamine Group</title>
          <description>Ketamine Group - - Receiving ketamine at 0.3 mg/given as IVP
Ketamine: Ketamine:0.3 mg/given as IVP</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="45"/>
            <count group_id="B2" value="45"/>
            <count group_id="B3" value="90"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.7" spread="10.5"/>
                    <measurement group_id="B2" value="34.8" spread="9.5"/>
                    <measurement group_id="B3" value="35.0" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Numeric Rating Scale of Pain score</title>
          <description>Numeric Rating Scale of Pain Score (0=no pain and 10=severe pain)</description>
          <units>score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.49" spread="1.5"/>
                    <measurement group_id="B2" value="8.64" spread="1.5"/>
                    <measurement group_id="B3" value="8.57" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Numeric Rating Scale of Pain</title>
        <description>We will compare efficacy as a difference between 2 groups in pain score at 30 minutes post-analgesic administration. The primary outcome is the difference between 2 groups in pain score at 30 minutes.
Pain will be measured via Numeric rating scale from 0 to 10 with 0 being no pain, 5 being moderate pain, and 10 being severe pain</description>
        <time_frame>30 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Morphine</title>
            <description>Morphine Group -- Receiving morphine at 0.1 mg /kg given as IVP
Morphine: Morphine: 0.1 mg /kg given as IVP</description>
          </group>
          <group group_id="O2">
            <title>Ketamine Group</title>
            <description>Ketamine Group - - Receiving ketamine at 0.3 mg/given as IVP
Ketamine: Ketamine:0.3 mg/given as IVP</description>
          </group>
        </group_list>
        <measure>
          <title>Numeric Rating Scale of Pain</title>
          <description>We will compare efficacy as a difference between 2 groups in pain score at 30 minutes post-analgesic administration. The primary outcome is the difference between 2 groups in pain score at 30 minutes.
Pain will be measured via Numeric rating scale from 0 to 10 with 0 being no pain, 5 being moderate pain, and 10 being severe pain</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.93" spread="3.1"/>
                    <measurement group_id="O2" value="4.07" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Within 2 hours of administration of either morphine or ketamine</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Morphine</title>
          <description>Morphine Group -- Receiving morphine at 0.1 mg /kg given as IVP
Morphine: Morphine: 0.1 mg /kg given as IVP</description>
        </group>
        <group group_id="E2">
          <title>Ketamine Group</title>
          <description>Ketamine Group - - Receiving ketamine at 0.3 mg/given as IVP
Ketamine: Ketamine:0.3 mg/given as IVP</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Nausea</description>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="45"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>Dizziness</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="45"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This was a single center study in which patients were enrolled as a convenience. There was the potential for unblinding as some participants exhibited ketamine specific reactions such as nystagmus.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Antonios Likourezos</name_or_title>
      <organization>Maimonides Medical Center</organization>
      <phone>718-283-6896</phone>
      <email>alikourezos@maimonidesmed.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

